A decision-ready blueprint
A governed AI agent solution designed around the commercial realities of cell & gene therapy developers.
Scientific, commercial, and digital architecture, with specialist expertise assembled where the engagement requires it.
Cell and gene therapy teams work across preclinical evidence, CMC information, clinical documentation, and commercial decisions that all require different forms of expertise and review. An agentic workflow is useful when it has a clear task, an approved body of information, and accountable people who can assess the output in context.
Lonrú Consulting designs and builds bounded agentic systems around that work. The objective is a practical tool that can prepare, compare, structure, or retrieve approved material for a defined decision without presenting automation as a substitute for scientific, quality, or commercial judgment.
We define the selected data sources, permissions, evidence boundaries, and working instructions, including the distinction between information that may be prepared for review and information that remains within a validated system of record.
A configured workflow performs a specific task, such as dossier preparation, evidence comparison, or scenario support, using only the approved context and controls agreed for the engagement.
Lonrú provides principal-led architecture and review governance. Depending on the work, final validation may be led by Lonrú, shared with client subject-matter experts, or owned by designated client SMEs.
Reviewed outputs are made usable through a dossier workspace, evidence view, portfolio interface, or decision tool that fits the existing operating rhythm.
Structure approved preclinical, CMC, and supporting material into a review-ready workflow without treating automated output as a submission or final technical decision.
Make the relevant evidence, open questions, risks, and next review actions easier to assess before a programme reaches a critical development gate.
Configure analysis around agreed clinical, manufacturing, and market assumptions so leadership can examine the basis for an asset or portfolio discussion.
Keep a clear record of the approved inputs, task boundary, review owner, and final decision for each useful output.
The first question is not which model to use. It is which decision or repeated task deserves a governed workflow, what it may access, and who must review the result. This provides a credible basis for a focused build rather than an unbounded automation programme.
The resulting system can support work around validated platforms while respecting the boundaries of those platforms and the authority of the people accountable for the final decision.
Relevant experience
40%+
Deployed Lonrú's ActiveArchitecture™ framework with Agentic Systems™ and Context Engineering™ guardrails. Automated compliance checks replaced manual clinical-document review steps, reducing operational turnaround times by more than 40% while preserving GxP and regulatory alignment.
Preclinical to IND
Created interactive Preclinical-to-IND decision-tree frameworks and risk-mitigation reports to help advanced-therapy enabling-technology companies align product capabilities with FDA IND validation requirements and reduce preclinical translation delays.
Architecture in context
Diagram summary: Cell and gene therapy evidence and development constraints are contextualised, analysed, and tested through ActiveArchitecture™, then reviewed for regulatory, portfolio, and commercial decisions.
Practical questions
Next step
Bring the decision, workflow, or delivery constraint that needs a clearer operating path.
Request a focused briefing